Reuters logo
8 months ago
BRIEF-Strongbridge Biopharma announces acquisition of U.S. rights to Keveyis from Taro
December 23, 2016 / 1:18 PM / 8 months ago

BRIEF-Strongbridge Biopharma announces acquisition of U.S. rights to Keveyis from Taro

Dec 23 (Reuters) - Strongbridge Biopharma Plc :

* Strongbridge Biopharma Plc says taro is also eligible to receive additional future payments upon achievement of certain sales unit milestones

* Strongbridge expects to commercially launch Keveyis in U.S. In April 2017

* Strongbridge Biopharma - under terms of purchase agreement, Strongbridge will provide taro with upfront and deferred payments of $8.5 million in two installments

* Strongbridge Biopharma - Taro has agreed to continue to manufacture Keveyis for Strongbridge under an exclusive supply agreement at least for period of Keveyis orphan exclusivity

* Strongbridge Biopharma Plc announces acquisition of U.S. Rights to Keveyis from Taro Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below